Clinical summary
Summary
This is a single arm study. Eligible participants will receive durvalumab (immunotherapy) at the same time as 4-cycles of cisplatin/carboplatin and etopside chemotherapy, which will be given as an intravenous infusion every three weeks for up to 12 weeks. Maintenance therapy with durvalumab will continue for 4 weeks once the chemotherapy cycles have been completed, until there is evidence of disease progression. Participants will also receive 10 chest radiotherapy sessions, which will take approx. 2 weeks to complete (given either concurrently with cycle 3 or 4 of chemotherapy (called concurrent radiotherapy) or within 6 weeks of finishing chemotherapy (called consolidation radiotherapy). Participants will be monitored throughout the study, for any adverse events or for progression of disease.Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
AstraZeneca
Scientific Title
A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer